Patents Represented by Attorney Arnold & Porter LLP
  • Patent number: 7067719
    Abstract: The present invention relates to a method for transforming Allium species with a heterologous gene using Agrobacterium.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: June 27, 2006
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventor: John Reynolds
  • Patent number: 7067722
    Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of monounsaturated to polyunsaturated fatty acids.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: June 27, 2006
    Assignee: Monsanto Technology LLC
    Inventor: JoAnne J. Fillatti
  • Patent number: 7056887
    Abstract: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of an exendin-4 molecule. The exendin-4 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: June 6, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Thomas R. Coolidge, Mario Ehlers
  • Patent number: 7053267
    Abstract: By this invention, modification of the fatty acid composition of a plant seed may be achieved as a result of the activity of a DNA sequence foreign to the plant species to be modified. In particular, it has been found that a plant oil having a modified fatty acid composition can be obtained upon the expression of genes derived from plants of different species than the host plant, upon the expression of genes derived from bacteria, and from the transcription of anti-sense sequences which are complementary to endogenous genes of the plant host cell. In a preferred embodiment, transcription of the fatty acid modifying foreign DNA sequence is restricted to the developing seed tissues.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: May 30, 2006
    Assignee: Calgene LLC
    Inventors: Vic C. Knauf, Gregory Thompson
  • Patent number: 7041872
    Abstract: By this invention, novel nucleic acid sequences encoding for acyl-CoA: cholesterol acyltransferase (ACAT) related proteins are provided, wherein said ACAT-like protein is active in the formation of a sterol ester and/or triacylylgycerol from a fatty acyl-CoA and sterol and/or diacylglycerol substrates. Also considered are amino acid and nucleic acid sequences obtainable from ACAT-like nucleic acid sequences and the use of such sequences to provide transgenic host cells capable of producing sterol esters and/or triacylglycerols.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: May 9, 2006
    Assignee: Calgene LLC
    Inventors: Michael W. Lassner, Diane M. Ruezinsky
  • Patent number: 7034110
    Abstract: A method for obtaining compounds having selected properties for a particular application by forming base modules having at least two structural diversity elements from the reaction of a first compound having at least one structural diversity element and a first reactive group, with a second compound having at least one structural diversity element and a second reactive group, wherein the first and second groups combine by an addition reaction; producing a first array of molecules by varying at least one of the structural diversity elements of the compounds when producing the base modules; and screening the array to determine a first suitable compound for the particular application. The base modules are preferably formed form oxazolone- and aminimide-derived compounds.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: April 25, 2006
    Assignee: ArQule, Inc.
    Inventor: Joseph C. Hogan, Jr.
  • Patent number: 6998387
    Abstract: A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: February 14, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Burkhard Goke, Christoph Beglinger, Thomas R. Coolidge
  • Patent number: 6998242
    Abstract: A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10?7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: February 14, 2006
    Assignee: Sankyo Co., Ltd.
    Inventors: Kazuki Yano, Fumie Kobayashi, Masaaki Goto, Naohiro Washida, Eisuke Tsuda, Kaoji Higashio, Yoshiji Yamada
  • Patent number: 6989366
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: January 24, 2006
    Assignee: Amylin PHarmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar
  • Patent number: 6982248
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: January 3, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers
  • Patent number: 6972351
    Abstract: Methods are provided for producing plants and seeds having altered carotenoid, fatty acid and tocopherol compositions. The methods find particular use in increasing the carotenoid levels in oilseed plants and in providing desirable high oleic acid seed oils.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: December 6, 2005
    Assignee: Calgene LLC
    Inventor: Christine K. Shewmaker
  • Patent number: 6970103
    Abstract: An event detection and storage system comprising: a vehicle detection device connected to an input vehicle, a traffic sign red light detector, a registered vehicles monitoring array, a control module that manipulates an infraction film in association with the registered vehicles monitoring array, a video capture device that supplies images to the control module, and reception device connected to the radar, an excess speed alert device, and a semaphore control connected to an output port, the system being configured in such manner that during the operation thereof there is generated the film such that when an event occurs, there is obtained a film of the moments that preceded the event, during the event and after the event. The invention also discloses an event detection method using the above system.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: November 29, 2005
    Inventor: Persio Walter Bortolotto
  • Patent number: 6956026
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: October 18, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Sunil Bhavsar
  • Patent number: 6936584
    Abstract: Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: August 30, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel R. A. Beeley, Kathryn Prickett, Kevin Beaumont
  • Patent number: 6924264
    Abstract: Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analogs, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: August 2, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. Prickett, Andrew A. Young
  • Patent number: 6919434
    Abstract: A protein which inhibits osteoclast diffraction and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: July 19, 2005
    Assignee: Sankyo Co., Ltd.
    Inventors: Masaaki Goto, Eisuke Tsuda, Shin'ichi Mochizuki, Kazuki Yano, Fumie Kobayashi, Nobuyuki Shima, Hisataka Yasuda, Nobuaki Nakagawa, Tomonori Morinaga, Masatsugu Ueda, Kanji Higashio
  • Patent number: 6919312
    Abstract: A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: July 19, 2005
    Assignee: Sankyo Co., Ltd.
    Inventors: Shinichi Mochizuki, Nobuaki Fujise, Chiharu Masuyama, Eisuke Tsuda, Kanji Higashio
  • Patent number: 6902744
    Abstract: Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: June 7, 2005
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Orville G. Kolterman, Andrew A. Young
  • Patent number: D507405
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: July 19, 2005
    Assignee: JanSport Apparel Corp.
    Inventors: Daniel Kim, Doug Golenz
  • Patent number: D521307
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: May 23, 2006
    Assignee: GLG Australia Pty Limited
    Inventors: Gary Parrant, Martin Robert Gaze